
Alethia Biotherapeutics is a clinical-stage biotechnology company focused on overcoming immune suppression and treatment resistance in metastatic cancers. Its lead candidate, sotevtamab (AB-16B5), targets epithelial-to-mesenchymal transition (EMT), a key driver of metastasis and immune evasion. By inhibiting EMT-associated resistance pathways and promoting a more immunologically active tumor environment, Alethia aims to improve the depth and durability of patient responses to therapy.
Annual Revenue$10M to $25M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.